摘要
目的分析晚期非小细胞肺癌(NSCLC)患者采用单药培美曲塞二线治疗的临床疗效。方法方便选取该院2011年1月—2017年12月收治的73例NSCLC患者,按照不同治疗方案随机分为实验组(37例,采用单药培美曲塞二线治疗)和对照组(36例,采用单药多西他赛治疗),对比两组患者临床控制率以及不良反应发生率。结果实验组患者临床控制率62.2%显著高于对照组50.0%,差异有统计学意义(χ~2=8.943,P<0.05),实验组患者疲乏(21.6%)、皮疹(2.7%)、脱发(5.4%)、腹泻(5.4%)、恶心呕吐(10.8%)、贫血(18.9%)、中性粒细胞减少(5.4%)等不良反应发生率均低于对照组55.6%、13.9%、36.1%、33.3%、44.4%、55.6%、55.6%。结论 NSCLC患者采用单药培美曲塞二线治疗可取得理想的临床效果,不良反应较轻,值得在临床上广泛推广应用。
Objective To analyze the clinical efficacy of single-agent pemetrexed second-line therapy in patients with ad- vanced non-small cell lung cancer （NSCLC）. Methods 73 patients with NSCLC admitted to the hospital from January 2011 to December 2017 were convenient selected and randomly divided into experimental group （37 cases, single-agent pemetrexed second-line treatment） and control group （36 cases, the single-agent docetaxel treatment）, compare the clinical control rate and the incidence of adverse reactions between the two groups. Results The clinical control rate of the experimental group was 62.2% significantly higher than that of the control group,50.0%,the difference was statistically significant （X^2= 8.943, P〈0.05）. The experimental group was fatigued （21.6%）, rash （2.7%）, alopecia （5.4%）, diarrhea （5.4%）, nausea and vomiting （10.8%）, anemia （18.9%）, neutropenia （5.4%） and other adverse reactions were lower than the control group 55.6%, 13.9%, 36.1%, 33.3%, 44.4%, 55.6%, 55.6%. Conclusion The second-line treatment with single-agent pemetrexed in patients with NSCLC can achieve ideal clinical results, and the adverse reactions are mild, which is worthy of widespread application in clinical practice.
作者
陆跃美
季锡林
张军玮
LU Yue-mei;Jl Xi-lin;ZHANG Jun-wei(Department of Oncology,Tongzhou District Hospital of Nantong,Nantong,Jiangsu Province,226300 China)
出处
《中外医疗》
2018年第27期134-135,138,共3页
China & Foreign Medical Treatment
关键词
晚期非小细胞肺癌
培美曲塞
多西他赛
疗效观察
Advanced non-small cell lung cancer
Pemetrexed
Doeetaxel
Efficacy observation
